... About us Where we come from Although firmly rooted in Germany, today we are very much a growing global business. As an integrated research and development company, we have a strong track record of bringing effective pain treatments and state-of-the-art technologies to patients. Our high level of investment in R&D is testament to our unwavering commitment to innovation. 1946 Foundation The Wirtz family founds Chemie Grünenthal GmbH in Stolberg, Germany. 1947 Penicillin Grünenthal is the first company in Germany to register penicillin after World War II. 1957 Thalidomide Thalidomide is launched; it was withdrawn from the market in 1961. Since its withdrawal from the market, Thalidomide and its tragic consequences have been part of our history – and they always will be. We support those affected by the tragedy and work to improve their daily lives. 1968 International expansion Grünenthal ventures overseas from Germany by founding an affiliate in Peru. 1977 Tramal® Tramal® is launched; it has since become one of the most frequently prescribed central acting analgesics worldwide. 2001 Transtec® Transtec®, an analgesic for chronic pain, is launched in Europe. The innovative transdermal patch with a polymer-based matrix system allows the patient to easily handle their pain medication. 2003 Zaldiar® Zaldiar® is launched globally as the first fixed-dose analgesic containing paracetamol and a small dose of Tramadol. This product is used for the treatment of acute pain. 2007 Versatis® Versatis®, a topically acting lidocaine patch used for the treatment of neuropathic pain after herpes zoster, is launched in the EU. 2010 Palexia® retard First launch of Palexia® retard in Europe: our tapentadol medication was the first innovative molecule in the centrally acting analgesic class approved in more than 25 years. 2013 Andrómaco We acquire Laboratorios Andrómaco S.A. and expand the business across Andean countries and Central America – a key milestone in the company’s global growth strategy. ... Visit Website Laboratorios Andrómaco S.A. 2014 Arcoxia® We begin to distribute Arcoxia® in several European countries and start to offer an innovative therapy for the treatment of pain with an inflammatory component. 2017 Zomig® We enter into an agreement with AstraZeneca for the global rights to Zomig® (Zolmitriptan), excluding Japan, a treatment used for the acute treatment of migraines and cluster headaches. This adds another major pain indication to our portfolio. 2018 NexiumTM and VimovoTM With the acquisition of the pain-related brands NexiumTM and VimovoTM, we conclude the biggest single investment in the history of the company. This acquisition significantly strengthens our leading position in pain management. 2018 QutenzaTM We establish our own commercial footprint in the United States by acquiring the US-rights for QutenzaTM (capsaicin) 8% patch. Thalidomide Thalidomide will always be a significant part of our company history. ... Visit website This website is for all those with an interest in the global business of Grünenthal Initiatives Grünenthal Health CHANGE PAIN® EFIC-Grünenthal Grant Societal Impact of Pain Grünenthal PRO Services Reporting side effects Follow us on LInkedIN Follow us on Instagram Contact Careers Memberships https://efpia.eu/ IFPMA Youtube Facebook Grünenthal 2021 © General Terms and Conditions Terms of Use Imprint Privacy Statement Privacy Statement HCP Sitemap